**Use of anti-inflammatory medication and risk and survival of endometrial cancer**

**Introduction:** Endometrial cancer is the most common gynecological cancer in Norway. 764 new cases were diagnosed in 2020, and also in Norway, incidence rates have risen dramatically over the last decades. There is a need for focused research for primary and secondary preventative measures. While non-steroidal anti-inflammatory drugs (NSAIDs) have been linked to reduced incidence and improved survival of certain cancers, the data in patients with endometrial cancer is conflicting.

**Objective/Aims:** The objective of this PhD-project is to provide more knowledge about the association between the use of NSAIDs and the risk and survival of endometrial cancer. Our primary aim is to study the association between the use of NSAIDs and the subsequent endometrial cancer risk. Our secondary aim is to study the use of NSAIDs after an endometrial cancer diagnosis and survival. Lastly we will explore association between the use of NSAIDs and subsequent risk of endometrial cancer for women at high risk of developing this type of cancer (women with high BMI). Different types of NSAIDs and dose levels will be studied.

**Study sample**: The project group will use a large population-based cohort of all Norwegian women born 1925-1986 for which information from the Norwegian Cancer Registry, the Norwegian Prescription Database and health surveys from the Norwegian Institute of Public Health are linked. Data sources such as the Cause of Death Registry and Statistics Norway will also be included. Further information and biometric data will be available from four large regional health studies in Norway (e.g., Cohort of Norway (CONOR), The Age 40 Program (HU40), Tromsø and Finnmark health study (TROFINN) and Romsås/Furuset health survey (MoRo I) from the Norwegian Institute of Public Health, and from questionnaires administered to women at mammography.

**Project group**: PhD candidate Ala Jabri Haug, Main supervisor Dr. Kristina Lindemann, Senior Researcher Dr. Renée Turzanski Fortner, Co-supervisor Dr. Franziska Siafarikas, Biostatistician and researcher Dr. Nathalie Støer, Biostatistician and researcher Dr. Edoardo Botteri and Senior researcher and Section Lead Dr. Hilde Langseth.

**Collaborators:** The project is a collaboration between Cancer Registry of Norway, University of Oslo, Akershus University Hospital and Oslo University Hospital.

**Results:** Abstract presented at ESGO 2023 - [ESGO2023-List-of-accepted-abstracts-2023\_final-Sept-14.pdf](https://congress.esgo.org/media/2023/09/ESGO2023-List-of-accepted-abstracts-2023_final-Sept-14.pdf)